Navigation Links
Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
Date:2/25/2010

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells a small population of cells within tumors that perpetuate cancer growth conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

One focus of attack is a chemical pathway within stem cells known as Notch, which scientists have shown is important for cancer stem cell growth. A new study published in the January 28 issue of Stem Cells by Charles Eberhart, M.D., Ph.D., associate professor of pathology, ophthalmology, and oncology at Johns Hopkins, now extends these findings to glioblastoma, the most common malignant brain tumor, and ultimately suggests other pathways and treatment with two or more drugs may need to be involved.

Eberhart based his conclusion on experiments in which he coaxed a glioblastoma cell line to form embryolike balls called neurospheres. Unlike most cells that will clump together in a culture dish, neurospheres more organized groups of neural cells can only form from stem cells. When Eberhart treated the neurospheres with a drug called GSI-18, which blocks the Notch pathway, the spheres were reduced by 70 percent or more. Eberhart also found that molecular markers typically found on the surface of brain cancer stem cells also plunged.

"This told us that the Notch pathway is a good target for drug development," says Eberhart, but further experiments suggested this approach may not be thorough enough.

In a second set of experiments, Eberhart collected the neurospheres that remained after treatment with the Notch-blocking drug and injected them into the brains of mice. The neurosphere transplants eventually grew into tumors and reignited the Notch pathway.

"This result suggested we didn't get rid of all the stem cells," says Eberhart, "so it's likely we may need to add more therapies or increa
'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... (PRWEB) November 28, 2014 Earlier ... reported during the hugely popular, 2014 MTV Video ... organization Truth launched ground-breaking celebrity centered television advertisements ... MTV viewership figures were estimated by Entertainment ... ads placed the spotlight on celebrities photographed by ...
(Date:11/28/2014)... New York (PRWEB) November 28, 2014 ... http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed in a ... recalled metal implants, Bernstein Liebhard LLP reports. ... in Bergen County Superior Court reflects the filing ... II modular-neck hip stems, which were voluntarily recalled ...
(Date:11/28/2014)... a leader in the wig industry, has announced a great ... promotion features: , > 400 pieces of FOUR ... (no coupon code needed), > 10% off for ... $49 , Visit http://www.uniwigs.com for more details , The ... 1st and the first 100 shoppers each day will receive our ...
(Date:11/28/2014)... November 28, 2014 Patten Pecans, based ... grown. With those passions driving them, they've added a ... Having tried other pecans oils, they've found this ... to be exceptionally flavorful, retaining the buttery pecan notes ... nutritional benefits found in pecans nuts is ...
(Date:11/28/2014)... 28, 2014 An inventor from Flint, Mich., ... day. "I got this idea while lying in a hospital ... he said. , The Bed Buddy provides a more ergonomic ... the bathroom. It eliminates the need to leave the bed, ... and dignity. Easy to use and producible in design variations, ...
Breaking Medicine News(10 mins):Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Carson M.D., professor of medicine and director of the Rebecca ... California, San Diego (UCSD) has identified a potent new anti-cancer ... South Pacific. The properties of somocystinamide A (ScA) are ... Proceedings of the National Academy of Science the week of ...
... A University of Alberta study recommends that workers on pig ... a child on a communal farm in Canada was diagnosed ... made a full recovery, health researchers were concerned because of ... multi-family community, who, fortunately, all demonstrated mild or no apparent ...
... $1 million, Five-year Grant, from New York State Department ... Becomes Lead,Poisoned, NEW YORK, Feb. 11 The ... at Montefiore,(CHAM) has been named one of three State ... regional healthcare delivery for children and,pregnant women with elevated ...
... lead to less controversial method of treating diseases , , ... they,ve reprogrammed human skin cells into ones with the ... that could aid in treating many diseases while sidestepping ... to become every cell type found in the human ...
... Inc.,(Nasdaq: NXXI ), the developer and marketer ... Iceland Health(R) brands that,help consumers manage blood sugar ... joint pain, today announced financial,results for the second ... 2007., The Company reported a 43% increase ...
... Feb. 11 Lincare Holdings,Inc. (Nasdaq: LNCR ), ... delivered to patients in the home, today announced,financial results ... 2007., For the quarter ended December 31, 2007, ... $368.1 million for the fourth quarter of,2006. The Company ...
Cached Medicine News:Health News:UCSD research team identifies novel anticancer drug from the sea 2Health News:Swine flu monitoring needed for farm workers, study says 2Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 2Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 4Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 5Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 6Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 7
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: